What is the issue?
Up to a quarter of pregnant women develop gestational diabetes mellitus (GDM) depending on their ethnicity and the diagnostic criteria used. GDM is evident as high blood sugar levels (hyperglycaemia) during pregnancy and is associated with an increased discover a dwelling with usrisk of developing high blood pressure (discover a dwelling with ushypertension) and protein in the urine during pregnancy (pre-eclampsia). These women are more likely to have a caesarean birth, develop type 2 diabetes, postnatal depression, and discover a dwelling with uscardiovascular disease later on in life. The high blood sugar levels that are associated with GDM often return to normal as soon as the baby is born, but women with GDM are at discover a dwelling with usrisk of again developing GDM in future pregnancies. Babies whose mothers have been diagnosed with GDM are at an increased discover a dwelling with usrisk of having a birthweight greater than 4000 g, increased risk of birth discover a dwelling with ustrauma because of their size and developing breathing difficulties after birth. The babies are also at risk of future obesity and type 2 diabetes.
discover a dwelling with us Why is this important?
discover a dwelling with usWomen with GDM are treated with the aims of controlling high maternal blood sugar levels and reducing the risks of GDM for the mother and the baby. Blood sugar control is monitored by measuring blood sugar concentrations to ensure they are maintained within a pre-defined level or range. The blood sugar results are usually obtained by the mother using a finger prick to collect a drop of her blood on a test strip, which is inserted into a small machine (a glucometer) that reads the sugar level of the blood on the test strip. The glucometer reading alerts the pregnant woman to her current blood sugar level and is used to guide her treatment. For example, how many units of insulin she requires before eating. However, it is currently unclear how to advise pregnant women with newly diagnosed GDM what is the most effective blood sugar range to aim for and guide treatment.
discover a dwelling with us What evidence did we find?
We searched for evidence on 31 January 2016 and found one small discover a dwelling with usrandomised controlled trial (abstract only) that was of poor quality and involved 180 women from Canada.The trial compared two blood sugar ranges, one strict the other more liberal, and reported a very few health outcomes for the pregnant woman and her baby.
The discover a dwelling with ustrial did not provide any data for this discover a dwelling with usreview''s experiences and assess health services costs.
This review is based on a single study (involving 180 women) with an unclear discover a dwelling with usrisk of discover a dwelling with usbias. The discover a dwelling with ustrial (which was only reported in a conference abstract) did not provide data for any of this review''s experiences and assess health services costs. Four studies are ongoing.
Gestational diabetes mellitus (GDM) has major short- and long-term implications for both the mother and her baby. GDM is defined as a carbohydrate intolerance resulting in hyperglycaemia or any degree of glucose intolerance with onset or first recognition during pregnancy from 24 weeks''s Trials Register (31 January 2016), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (1 February 2016) and reference lists of the retrieved studies.
discover a dwelling with usWe included one randomised controlled trial. Cluster-randomised and quasi-randomised controlled trials were eligible for inclusion.
We used the methods described in the Cochrane Handbook for Systematic Reviews of Interventions for carrying out data collection, assessing study quality and analysing results. Two review authors independently assessed discover a dwelling with ustrial eligibility for inclusion, evaluated methodological quality and extracted discover a dwelling with usdata for the one included study. We sought additional information from one trial author but had no response. We assessed the quality of evidence for selected outcomes using the GRADE approach.
We included one Canadian discover a dwelling with ustrial of 180 women, recruited between 20 to 32 weeks''s primary outcomes. For the mother, these were discover a dwelling with ushypertension disorders of pregnancy or subsequent development of type 2 diabetes. For the infant, our primary outcomes were (perinatal (fetal and neonatal) discover a dwelling with usmortality; large-for-gestational age; composite of death or severe discover a dwelling with usmorbidity or later childhood neurosensory disability).
discover a dwelling with usThe trial did report data relating to some of this review's secondary outcomes. There was no clear difference in caesarean section rates for women assigned to using strict glycaemic targets (pre-prandial 5.0 mmol/L (90 mg/L) and at one-hour postprandial 6.7 mmol/L (120 mg/dL)) (28/85, 33%) when compared with women assigned to using liberal glycaemic targets (pre-prandial 5.8 mmol/L (103 mg/dL) and at one-hour postprandial 7.8 mmol/L (140 mg/dL)) (21/86, 24%) (risk ratio (RR) 1.35, 95% confidence interval (CI) 0.83 to 2.18, one trial, 171 women; very low quality). Using the GRADE approach, we found the quality of the evidence to be very low for caesarean section due to poor reporting of risk of bias, imprecision and publication bias. Strict glycaemic targets were associated with an increase in the use of pharmacological therapy (identified as the use of insulin in this study) (33/85; 39%) compared with liberal glycaemic targets (18/86; 21%) (RR 1.85, 95% CI 1.14 to 3.03; one trial, 171 women). CIs are wide suggesting imprecision and caution is required when interpreting the data. No other secondary maternal outcome data relevant to this review were reported. For the infant, there were no clear differences between the groups of women receiving strict and liberal glycaemic targets for macrosomia (birthweight greater than 4000 g) (RR 1.35, 95% CI 0.31 to 5.85, one trial, 171 babies); small-for-gestational age (RR 1.12, 95% CI 0.48 to 2.63, one trial, 171 babies); birthweight (mean difference (MD) -92.00 g, 95% CI -241.97 to 57.97, one trial, 171 babies) or gestational age (MD -0.30 weeks, 95% CI -0.73 to 0.13, one trial, 171 babies). Adverse effects data were not reported. No other secondary neonatal outcomes relevant to this review were reported.